Skip to main content

multiple myeloma

Conference Coverage
12/10/2022
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues...
12/10/2022
Journal of Clinical Pathways
Dr Fonseca
Videos
12/13/2021
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic,...
12/13/2021
Oncology
NCCN Updates Clinical Practice Guideline for Multiple Myeloma
03/15/2021
The National Comprehensive Cancer Network released an update to its clinical practice guideline for multiple myeloma.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for multiple myeloma.
The National Comprehensive...
03/15/2021
Journal of Clinical Pathways
News
02/01/2021
Journal of Clinical Pathways
News
06/26/2020
A post-hoc analysis presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) led to a new risk prediction score for early severe infection in patients with multiple myeloma. Many...
A post-hoc analysis presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) led to a new risk prediction score for early severe infection in patients with multiple myeloma. Many...
A...
06/26/2020
Journal of Clinical Pathways
News
06/22/2020
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
...
06/22/2020
Journal of Clinical Pathways
News
06/18/2020
Isatuximab in combination with pomalidomide and dexamethasone may provide an effective treatment option in relapsed or refractory multiple myeloma, including difficult-to-treat subgroups of these patients, and may...
Isatuximab in combination with pomalidomide and dexamethasone may provide an effective treatment option in relapsed or refractory multiple myeloma, including difficult-to-treat subgroups of these patients, and may...
...
06/18/2020
Journal of Clinical Pathways
Feature
08/17/2017
Abstract: Multiple myeloma (MM) is a progressive and fatal disease, primarily affecting men aged 66 years or older. Because MM is primarily a disease of the elderly, it is incumbent on geriatricians and primary care...
Abstract: Multiple myeloma (MM) is a progressive and fatal disease, primarily affecting men aged 66 years or older. Because MM is primarily a disease of the elderly, it is incumbent on geriatricians and primary care...
...
08/17/2017
Journal of Clinical Pathways
Author Insights
08/14/2017
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a...
08/14/2017
Journal of Clinical Pathways